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Background: The REG1 System, a FIXa inhibitor RB006 and its active control agent RB007, has shown predictable anticoagulation in humans 
following intravenous (IV) administration. The behavior of such agents when administered subcutaneously (SC) has not been explored. We tested the 
first SC administration of the aptamer, RB006, paired with IV administration of the control agent, RB007, for its effects on coagulation.
Methods: 2 studies were conducted in cynomolgus monkeys. A PK/PD study (n=4) designed to evaluate the effects of single and repeat SC doses 
of RB006 with and without IV RB007, and a repeat-dose safety study (n=32) at doses of RB006 ranging from 0.5 to 5 mg/kg SC every other day for 
14 days.
Results: Single RB006 doses resulted in peak anticoagulation at 12 hours, which persisted until at least 48 hours (see figure), and decayed 
over 7 days. Every other day administration of RB006 resulted in plasma accumulation. Administration of RB007 at the time of RB006 peak effect 
neutralized the absorbed RB006 but did not further affect absorption of RB006 remaining at the site of injection. Every other day administration of 5 
mg/kg RB006 for 14 days was well tolerated.
Conclusions: SC administration of RB006 was well tolerated by monkeys and achieved prolonged anticoagulation that was reversible by RB007. 
This represents the first successful SC application of an aptamer. The prolonged anticoagulant effect and reversibility may provide a new approach to 
chronic anticoagulation for future clinical studies.
